Xencor reported $53.94M in Cash and Equivalent for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US USD 866.39M 206.83M
Amgen AMGN:US USD 9.3B 197M
Arrowhead Research ARWR:US USD 202.25M 94.24M
AstraZeneca AZN:LN USD 6.17B 1.71B
Biogen BIIB:US USD 3.42B 256.3M
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Cytokinetics CYTK:US USD 65.58M 40.66M
GlaxoSmithKline GSK:LN GBP 3.72B 117M
Karyopharm Therapeutics KPTI:US USD 277.97M 206.62M
Macrogenics MGNX:US USD 108.88M 24.89M
Novartis NOVN:VX USD 7.52B 1.21B
Regeneron Pharmaceuticals REGN:US USD 14.33B 10.84B
Roche Holding ROG:VX 4.99B 676M
Seattle Genetics SGEN:US USD 319.94M 42.66M
Xencor XNCR:US USD 53.94M 1.29M